

Tumor necrosis factor- α -induced a disintegrin and metalloprotease 10 increases apoptosis resistance in prostate cancer cells

LI BING ZHU^{1,2}, SHENG TAO ZHAO³, TING ZHAO XU² and HE WANG⁴

¹Department of Urology, The People's Liberation Army Mount Lu Sanatorium, Jiujiang, Jiangxi 332000;

²Department of Urology, Fuzhou General Hospital of Nanjing Military Area Command, Fuzhou, Fujian 350000;

³Department of Respiratory Medicine, Kunming General Hospital of Chengdu Military Area Command,

Kunming, Yunnan 650000; ⁴Department of Urology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China

Received June 27, 2013; Accepted December 20, 2013

DOI: 10.3892/ol.2014.1810

Abstract. In developed countries, prostate cancer (PCa) is the second most frequently diagnosed type of cancer and the third most common cause of cancer-related mortality in males. Compared with western countries, the morbidity rate of PCa in China is markedly lower, however, it is rising annually. The etiology of PCa is unclear, therefore, to investigate how a disintegrin and metalloprotease 10 (ADAM10) functions in PCa, ADAM10 mRNA and protein levels induced by tumor necrosis factor (TNF)- α were identified using polymerase chain reaction and flow cytometry, respectively. To investigate the mechanism of ADAM10 activity in PCa, specific inhibitors were used, and DNA transfection and RNA interference technology were employed to identify the interaction between ADAM10 and the Fas ligand (L). The results indicated that TNF- α induced ADAM10 expression in a time- and dose-dependent manner through the p38 mitogen-activated protein kinase/necrosis factor- κ B signaling pathway. ADAM10 hydrolyzed FasL and contributed to apoptosis resistance of the tumor cells. These observations indicate a promising therapeutic modality for the treatment of apoptosis-resistant PCa, by targeting ADAM10 sheddase activity.

Introduction

Prostate cancer (PCa) is a complex and biologically heterogeneous disease (1) and there is currently no cure for advanced, hormone-refractory PCa (2). PCa is the second leading cause

of cancer mortality in males >40 years of age in the USA (3) and the third most common cause of cancer-related mortality in males (4). PCa is generally a slow developing type of cancer, and 5- and 10-year relative survival rates of early stage PCa are 99 and 95%, respectively (5). Compared with western countries, the Chinese population exhibits a lower incidence of PCa, however, it is increasing annually, in addition to an increased average life expectancy, improved dietary patterns and enhanced diagnosis technology. There are numerous risk factors that induce PCa, such as specific hormones, age, ethnicity and family history. Regardless of other factors, a family history of PCa is the strongest known risk factor (6).

Speculation regarding an association between inflammation and cancer has been considered for some time and epidemiological studies have established that numerous tumors occur alongside chronic infectious diseases (7). Prostatitis is a common clinical disease, which is associated with renal surgery and it is also known that diet and sexually transmitted infections increase the risk of PCa (8). During the development of PCa, tumor cells and the microenvironment of the local host tissue interact and form a tumor-host microenvironment (9). The tumor-host microenvironment is composed of tumor cells, numerous types of host cells, extracellular matrices and various sources of secretory factors, which can modify the local extracellular matrix (ECM), stimulate migration and promote proliferation and survival (10). Proteases are fundamental to numerous biological processes and are associated with a wide variety of pathological conditions, including cancer (11). Matrix metalloproteinases (MMPs) are a large family of calcium-dependent zinc-containing endopeptidases, which are responsible for tissue remodeling and degradation of the ECM (12). As digestion of the ECM is essential for tumor invasion and metastasis, the role of MMPs in the later stages of tumor development has been studied (13).

A disintegrin and metalloproteinases (ADAMs) are a family of proteins with a sequence that exhibits similarities to the repolysin family of snake venom metalloproteinases (14); ADAMs share the metalloproteinase domain with the MMPs (15). Functional ADAMs are involved in ectodomain

Correspondence to: Dr He Wang, Department of Urology, Tangdu Hospital, The Fourth Military Medical University, 1 Xinshi Road, Xi'an, Shaanxi 710038, P.R. China
E-mail: hewangjiujiang@163.com

Key words: prostate cancer, a disintegrin and metalloproteinase 10, fas ligand, tumor necrosis factor- α , apoptosis

shedding of diverse growth factors, cytokines, receptors and adhesion molecules (16). Furthermore, pathologies, such as inflammation and cancer, involve specific ADAM family members, including ADAM10 (17). Dysregulation of ADAM10 in inflammation and disease has lead to the use of the catalytic domain of the protein as a therapeutic target; however, ADAM10 also appears to play important roles in normal states (18). *In vitro*, ADAM10 has been implicated in E-cadherin cleavage within keratinocytes and gastric cancer cell lines (19,20). Moreover, in the prostate, the membranous ADAM10 expression was observed to be high in benign prostatic hyperplasia patient samples, and the nuclear translocation of ADAM10 coupled with the androgen receptor was involved in human PCa tumor growth and progression (21).

Previous studies have indicated that ADAM10 participates in PCa development, however, the mechanism has not been investigated. In the present study, TNF- α was identified as a specific inducer of ADAM10 protein expression in the PCa cell line, PC-3, and demonstrated the regulatory function that exists between tumor necrosis factor (TNF)- α and ADAM10 regarding gene expression and protein levels. Furthermore, it was identified that TNF- α regulates ADAM10 through the p38 mitogen activated protein (MAPK)/necrosis factor (NF)- κ B signaling pathway. In addition, the effects of ADAM10 on Fas ligand (FasL) and cell apoptosis were investigated.

Materials and methods

Reagents and antibodies. Recombinant human TNF- α , anti-TNF- α and anti-ADAM10 antibody were purchased from Sigma-Aldrich Chemie B.V. (Zwijndrecht, Netherlands). An RNeasy kit was provided by Gibco-BRL (Gaithersburg, MD, USA) and an enhanced chemiluminescence (ECL) kit was provided by Boehringer Ingelheim (Berlin, Germany). The following were obtained from Invitrogen Life Technologies (Carlsbad, CA, USA): Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit, expression vector pGEX-4T-1, pcDNATM3.1/myc-His, fetal calf serum (FCS), RPMI-1640 medium, nitrocellulose membranes for western blot analysis, a polymerase chain reaction (PCR) kit and LipofectamineTM 2000. FITC-labeled goat anti-mouse IgG (H+L), anti-p38MAPK, anti-phospho-p38MAPK and anti-NF- κ B antibodies were obtained from Millipore (Billerica, MA, USA) and SB 203580 and pyrrolidine dithiocarbamate (PDTC) were purchased from Calbiochem (San Diego, CA, USA). The primers that were used in the present study were synthesized by Shanghai Sangon Company (Shanghai, China) and small interfering RNA (siRNA), small interfering ADAM10 (si-ADAM10) and non-silencing siRNA (si-control) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Unless otherwise specified, all of the other reagents were of an analytical grade.

Cell culture. The human PCa cells, PC-3 and Epstein-Barr virus-transformed B371 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were maintained in RPMI-1640 medium, which was supplemented with 10% (v/v) heat-inactivated FCS and penicillin-streptomycin-mixed solution in a humidified incubator with 95% air and 5% CO₂. The medium was changed every 2-3 days

and the cell concentration was $\sim 10^6$ cell/ml. The experiments were conducted on cells in exponential growth. The study was approved by the ethics committee of The People's Liberation Army Mount Lu Sanatorium (Jiujiang, China).

RNA preparation and PCR. Total RNA was isolated from the untreated control cells and the TNF- α -treated cells using the RNeasy kit according to the manufacturer's instructions. PCR was performed according to the manufacturer's instructions and the PCR products were resolved on a 100 g/l agarose gel and visualized using ethidium bromide transillumination under ultraviolet light. β -actin served as an internal control to evaluate the efficiency of cDNA synthesis and the PCR amplification. The primer sequences were as follows: ADAM10 forward, 5'-TCCACAGCCCATTTCAGCAA-3' and reverse, 5'-AGGCACTAGGAAGAACCAA-3'; and β -actin forward, 5'-TCACCCACACTGTGCCCATTCTACGA-3' and reverse, 5'-CAGCGGAACCGCTCATTGCCAATGG-3'.

Flow cytometric analyses of ADAM10 surface expression. Flow cytometry was employed to detect the ADAM10 protein expression on the surface of the cells. Following treatment with TNF- α , the nonspecific antibody-binding sites of the PC-3 cells were blocked via incubation with 5% rabbit serum in Dulbecco's phosphate-buffered saline. Anti-ADAM10 antibody was subsequently added and incubated at 4°C for 30 min. After washing, the cells were incubated with FITC-labeled goat anti-mouse IgG and analyzed by flow cytometry (FACSCalibur flow cytometer, BD Biosciences, San Jose, CA, USA).

Western blot analysis. The samples were separated using 10% SDS-PAGE and transferred on to a nitrocellulose membrane. The western blot analyses were performed as previously described (22) with minor modifications. The blot was incubated using anti-p38MAPK, anti-phospho-p38MAPK and anti-NF- κ B antibodies, and visualized with horseradish peroxidase-conjugated anti-rabbit IgG and an ECL-Plus chemiluminescence detection system (GE Healthcare, Pittsburgh, PA, USA).

DNA transfection. The segments of FasL and ADAM10 in the human PC-3 cells were amplified using PCR. The PCR-amplified ADAM10 and FasL segments were subcloned into pGEX-4T-1 and pcDNA3.1/myc-His, respectively and the B371 cells were seeded into a 24-well plate at a density of 10^5 cells/well. B371 cells were transfected with an ADAM10 and/or FasL expression vector for 5 h in serum-free media using Lipofectamine 2000, according to the manufacturer's instructions.

Measurement of FasL using ELISA. The concentrations of soluble FasL (sFasL) were measured using ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. All samples were run in duplicate and the average was obtained.

RNA interference. To knock down ADAM10 expression at the mRNA level, 5×10^5 cells/well were seeded in complete medium in a 24-well plate. ADAM10 siRNA was transfected




Figure 1. TNF- α induces ADAM10 expression in a time- and dose-dependent manner. PC-3 cells were treated with varying concentrations of TNF- α for 24 h and ADAM10 (A) mRNA and (B) protein expression was analyzed using PCR and flow cytometry, respectively. TNF- α (10 ng/ml) was used to treat PC-3 cells at various time-points and ADAM10 (A) mRNA and (B) protein expression was analyzed using PCR and flow cytometry, respectively. (E) ADAM10 expression was inhibited following the application of anti-TNF- α antibody. * $P < 0.05$ and ** $P < 0.01$, vs. control; # $P < 0.05$, vs. TNF- α treatment group. ADAM10, a disintegrin and metalloprotease 10; TNF, tumor necrosis factor; PCR, polymerase chain reaction.

using Lipofectamine 2000 according to the manufacturer's instructions.

Statistical analysis. All data are expressed as the mean \pm standard deviation. Data were compared by one-way analysis of variance and pairwise comparison procedures were conducted using Tukey's test. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

TNF- α induces ADAM10 expression. ADAM10 expression was observed in untreated PC-3 cells, however, expression was significantly increased following the addition of TNF- α in a dose-dependent manner ($P < 0.05$; Fig. 1A and B). The ADAM10 expression increased in a time-dependent manner and peaked at 24 h in response to 10 ng/ml TNF- α stimulation (Fig. 1C and D). Moreover, the addition of anti-TNF- α neutralized TNF- α , and TNF- α -induced ADAM10 expression was attenuated ($P < 0.05$; Fig. 1E). The results indicated that ADAM10 expression was markedly increased as a result of TNF- α stimulation in a time- and dose-dependent manner.

TNF- α upregulates ADAM10 expression via the p38MAPK/NF- κ B pathway. As TNF- α -induced ADAM10 expression was upregulated via the p38MAPK/NF- κ B pathway, phosphorylated-p38MAPK, p38MAPK and intranuclear NF- κ B protein expression was measured in the PC-3 cells. Phosphorylated-p38MAPK and intranuclear NF- κ B were rarely observed in the untreated control PC-3 cells, however, upon TNF- α stimulation for 15 min, the expression of the two significantly increased (Fig. 2A). The expression of ADAM10 was markedly reduced following addition of the p38MAPK inhibitor,




Figure 2. TNF- α upregulates ADAM10 expression via the p38MAPK/NF- κ B pathway. (A) TNF- α (10 ng/ml) was administered to treat the PC-3 cells at three time-points. Western blot analysis showed that phosphorylated-p38MAPK and intranuclear-NF- κ Bp65 were markedly increased from 15 min. (B) PC-3 cells were pretreated with the p38MAPK inhibitor, SB, or the NF- κ B inhibitor, PDTC, for 1 h and incubated with 10 ng/ml TNF- α for 24 h. Flow cytometry of the ADAM10 cell surface protein expression was conducted. * $P < 0.05$ and ** $P < 0.01$, vs. TNF- α treatment group. TNF, tumor necrosis factor; MAPK, mitogen-activated protein kinase; ADAM10, a disintegrin and metalloprotease 10; NF- κ B, nuclear factor- κ B; SB, SB 203580; PDTC, pyrrolidine dithiocarbamate; DMSO, dimethyl sulfoxide.

SB 203580, and the NF- κ B inhibitor, PDTC ($P < 0.05$; Fig. 2B). These observations indicated that the ADAM10 expression was upregulated by TNF- α through the p38MAPK/NF- κ B pathway.

ADAM10 involvement in the cleavage of FasL. To determine whether ADAM10 is responsible for FasL cleavage, the release of sFasL into the culture medium of FasL-transfected B371 cells (FasL-6X His) was investigated using ELISA. A marked effect on FasL shedding was observed in FasL⁺ADAM10⁺B371 cells, when compared with the B371 and FasL⁺B371 cells ($P < 0.05$; Fig. 3). These data indicate that ADAM10 may be responsible for the cleavage of FasL.

ADAM10 expression inhibits FasL-mediated apoptosis. To further certify the involvement of ADAM10 in shedding, B371 (ADAM10⁺FasL⁺) and PC-3 cells were treated with ADAM10 siRNA and cell apoptosis was analyzed. The results indicated that compared with the control, treatment of B371 and PC-3 cells with ADAM10 siRNA resulted in a significant increase in apoptosis ($P < 0.05$; Fig. 4A and B), therefore indicating that ADAM10 expression increases the resistance of the cells to apoptosis.

Discussion

ADAM10 has been shown to exhibit substrate specificity, which overlaps with MMPs, thus indicating that ADAM10 has potential ECM-remodeling capabilities (23). Furthermore, ADAM10 may be critical during development and in adult tissues (21). ADAM10 is predominantly a sheddase, which is known to cleave epidermal growth factor (EGF)-like ligands from the cell surface and promote EGF receptor family signaling (24). TNF- α is a cytokine involved in systemic and acute inflammation (25). TNF- α has been implicated in inflammation-associated cancer and is produced by tumor cells and/or infiltrating leukocytes (26). In the present study, the results indicated that ADAM10 expression was increased following TNF- α stimulation in a time- and dose-dependent manner. Moreover, the TNF- α -induced ADAM10 expression was attenuated following the application of anti-TNF- α .

The p38MAPK signaling pathway is critical in normal immune and inflammatory responses (27) and is activated by numerous extracellular mediators of inflammation, including chemoattractants, cytokines, chemokines and bacterial lipopolysaccharides (28). TNF- α is able to activate the p38MAPK signaling pathway (29) and p38MAPK is key in the production of proinflammatory cytokines, in addition to being able to regulate cytokine expression by modulating transcription factors, such as NF- κ B (30). Upon stimulation by TNF- α , TNF receptor (TNF-R)-1 recruits various groups of adaptor proteins, which are required for the activation of NF- κ B inhibitor kinase (31) and induces the activation of the NF- κ B signaling pathway (32). In the present study, TNF- α -induced ADAM10 expression, which demonstrated that in the local tumor microenvironment a variety of cells regulate the expression of tumor-associated molecules through paracrine and autocrine pathways, with important implications in the occurrence of tumors and their development and metastasis. p38MAPK and NF- κ B inhibition resulted in lower ADAM10 expression, which indicate that TNF- α upregulated ADAM10




Figure 3. ADAM10 is involved in FasL shedding and results in increased sFasL release in the transfected B371 cells. B371 cells were transfected with recombinant FasL-6X His and/or recombinant ADAM10-glutathione *S*-transferase constructs for 24 h. Post-transfection, cells were harvested to measure the extent of apoptosis. * $P < 0.05$, vs. control; # $P < 0.05$ vs. FasL⁺B371 cells. sFasL, soluble Fas ligand; ADAM10, a disintegrin and metalloprotease 10.




Figure 4. ADAM10 expression inhibits FasL-mediated apoptosis. B371 (FasL⁺ADAM10⁺) and PC-3 cells were transfected using control siRNA or ADAM10 siRNA for 24 h. Post-transfection, the cells were harvested to measure the extent of apoptosis. * $P < 0.05$, vs. control. ADAM10, a disintegrin and metalloprotease 10; siRNA, small interfering RNA; FasL, Fas ligand.

expression through the p38MAPK/NF- κ B pathway in patients with PCa.

The cell surface-bound receptor Fas (also termed APO-1 or CD95) belongs to a subgroup of the TNF-R family, which contains an intracellular death domain and triggers apoptosis. Furthermore, FasL is a member of the TNF cytokine family (33). A previous study identified that cytotoxic T cells, which express FasL in its membrane-bound form (mFasL) on their surface, are able to kill Fas⁺ target cells (34). The Fas/FasL system is significant in tumorigenesis and a previous investigation

has indicated that the impairment of the Fas/FasL system in cancer cells may lead to apoptosis resistance and contribute to tumor progression (35). ADAM10 downregulates the Fas/FasL signaling pathway through Fas shedding (36), which results in increased sFasL. In the present study, the results indicated that ADAM10 was involved in FasL shedding and ADAM10 expression inhibited FasL-mediated apoptosis. ADAM10, as an active metalloprotease, influenced the tumor via numerous pathways and may have participated in apoptosis-related protein hydrolysis. Malignant tumor development may, therefore, be associated with FasL loss by escaping the Fas/FasL scavenge system. sFasL is important during cell apoptosis as it is able to bind to Fas and act as an antagonist within the Fas/mFasL conjugate, which suppresses cell apoptosis. In PCa, increased levels of sFasL may compete with mFasL and bind to Fas, thus, blocking FasL-mediated apoptosis. Therefore, increased sFasL expression in the tumor cell microenvironment may be a mechanism of immune evasion. In conclusion, the present study indicated that ADAM10 hydrolyzed mFasL in patients with PCa, which increased the local sFasL concentration. Further investigation is required to establish whether ADAM10 may serve as a target for chemotherapeutic agents.

Acknowledgements

This study was supported by the Natural Science Funds of Fujian Province (no. 2010J05079).

References

1. Fox JJ, Schöder H and Larson SM: Molecular imaging of prostate cancer. *Curr Opin Urol* 22: 320-327, 2012.
2. Ouyang DY, Xu LH, He XH, *et al*: Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. *Autophagy* 9: 20-32, 2013.
3. Hao Y, Zhao Y, Zhao X, *et al*: Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. *Cancer Invest* 29: 318-324, 2011.
4. Damber JE and Aus G: Prostate cancer. *Lancet* 371: 1710-1721, 2008.
5. Eastham JA, May RA, Whatley T, Crow A, Venable DD and Sartor O: Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. *J Natl Cancer Instit* 90: 756-760, 1998.
6. Mononen N and Schleutker J: Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. *J Urol* 181: 1541-1549, 2009.
7. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer: new molecular links. *Ann NY Acad Sci* 1155: 206-221, 2009.
8. Coyle YM: Lifestyle, genes, and cancer. *Methods Mol Biol* 472: 25-56, 2009.
9. Wu H, Haag D, Muley T, *et al*: Tumor-microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma. *Genes Chromosomes Cancer* 52: 250-264, 2013.
10. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. *Nature* 411: 375-379, 2001.
11. López-Otín C and Matrisian LM: Emerging roles of proteases in tumour suppression. *Nat Rev Cancer* 7: 800-808, 2007.
12. Hua H, Li M, Luo T, Yin Y and Jiang Y: Matrix metalloproteinases in tumorigenesis: an evolving paradigm. *Cell Mol Life Sci* 68: 3853-3868, 2011.
13. Orlichenko LS and Radisky DC: Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. *Clin Exp Metastasis* 25: 593-600, 2008.
14. Mochizuki S and Okada Y: ADAMs in cancer cell proliferation and progression. *Cancer Sci* 98: 621-628, 2007.
15. Rocks N, Paulissen G, El Hour M, *et al*: Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. *Biochimie* 90: 369-379, 2008.
16. Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. *Mol Aspects Med* 29: 258-289, 2008.
17. Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. *Genes Dev* 17: 7-30, 2003.
18. Grabowska MM, Sandhu B and Day ML: EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. *Cell Signal* 24: 532-538, 2012.
19. Maretzky T, Scholz F, Köten B, Proksch E, Saftig P and Reiss K: ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis. *J Invest Dermatol* 128: 1737-1746, 2008.
20. Schirrmeyer W, Gnad T, Wex T, *et al*: Ectodomain shedding of E-cadherin and c-Met is induced by *Helicobacter pylori* infection. *Exp Cell Res* 315: 3500-3508, 2009.
21. Arima T, Enokida H, Kubo H, *et al*: Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. *Cancer Science* 98: 1720-1726, 2007.
22. Liu WH and Chang LS: Piceatannol induces Fas and FasL up-regulation in human leukemia U937 cells via Ca²⁺/p38alpha MAPK-mediated activation of c-Jun and ATF-2 pathways. *Int J Biochem Cell Biol* 42: 1498-1506, 2010.
23. McCulloch DR, Akl P, Samarantunga H, Herington AC and Odorico DM: Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. *Clin Cancer Res* 10: 314-323, 2004.
24. Blobel CP: ADAMs: key components in EGFR signalling and development. *Nat Rev Mol Cell Biol* 6: 32-43, 2005.
25. Lamour NF, Wijesinghe DS, Mietla JA, Ward KE, Stahelin RV and Chalfant CE: Ceramide kinase regulates the production of tumor necrosis factor alpha (TNFalpha) via inhibition of TNFalpha-converting enzyme. *J Biol Chem* 286: 42808-42817, 2011.
26. Szlosarek PW and Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. *Lancet Oncol* 4: 565-573, 2003.
27. Cuadrado A and Nebreda AR: Mechanisms and functions of p38 MAPK signalling. *Biochem J* 429: 403-417, 2010.
28. Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiol Mol Biol Rev* 75: 50-83, 2011.
29. Chung KF: p38 mitogen-activated protein kinase pathways in asthma and COPD. *Chest* 139: 1470-1479, 2011.
30. Karin M: Nuclear factor-kappaB in cancer development and progression. *Nature* 441: 431-436, 2006.
31. Bhoj VG and Chen ZJ: Ubiquitylation in innate and adaptive immunity. *Nature* 458: 430-437, 2009.
32. Karin M and Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 5: 749-759, 2005.
33. Strasser A, Jost PJ and Nagata S: The many roles of FAS receptor signaling in the immune system. *Immunity* 30: 180-192, 2009.
34. Krammer PH: CD95's deadly mission in the immune system. *Nature* 407: 789-795, 2000.
35. Villa-Morales M and Fernández-Piqueras J: Targeting the Fas/FasL signaling pathway in cancer therapy. *Expert Opin Ther Targets* 16: 85-101, 2012.
36. Liu WH and Chang LS: Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. *Int J Biochem Cell Biol* 43: 1708-1719, 2011.